Spinal cord injury (SCI) is a devastating condition with variability in injury mechanisms and neurologic recovery. Spinal cord impairment after SCI is measured and classified by a widely accepted standard neurological examination. In the very acute stages post-injury, however, this examination is extremely challenging (and often impossible) to conduct and has modest prognostic value in terms of neurological recovery. The lack of objective tools to classify injury severity and predict outcome is a barrier for clinical trials and thwarts development of therapies for those with SCI. Biological markers (biomarkers) represent a promising, complementary approach to these challenges because they represent an unbiased approach to classify injury severity and predict neurological outcome. Identification of a suitable panel of molecular biomarkers would comprise a fundamental shift in how patients with acute SCI are evaluated, stratified, and treated in clinical trials. MicroRNA are attractive biomarker candidates in neurological disorders for several reasons, including their stability in biological fluids, their conservation between humans and model mammals, and their tissue specificity. In this study, we used next-generation sequencing to identify microRNA associated with injury severity within the cerebrospinal fluid (CSF) and serum of human patients with acute SCI. The CSF and serum samples were obtained 1–5 days post-injury from 39 patients with acute SCI (24 American Spinal Injury Association Impairment Scale [AIS] A, 8 AIS B, 7 AIS C) and from five non-SCI controls. We identified a severity-dependent pattern of change in microRNA expression in CSF and identified a set of microRNA that are diagnostic of baseline AIS classification and prognostic of neurological outcome six months post-injury. The data presented here provide a comprehensive description of the CSF and serum microRNA expression changes that occur after acute human SCI. This data set reveals microRNA candidates that warrant further evaluation as biomarkers of injury severity after SCI and as key regulators in other neurological disorders.
Get full access to this article
View all access options for this article.
References
1.
NoonanV.K., FingasM., FarryA., BaxterD., SinghA., FehlingsM.G., and DvorakM.F. (2012). Incidence and prevalence of spinal cord injury in Canada: a national perspective. Neuroepidemiology, 38, 219–226.
2.
SinghA., TetreaultL., Kalsi-RyanS., NouriA., and FehlingsM.G. (2014). Global prevalence and incidence of traumatic spinal cord injury. Clin. Epidemiol. 6, 309–331.
3.
PriebeM.M., ChiodoA.E., ScelzaW.M., KirshblumS.C., WuermserL.A., and HoC.H. (2007). Spinal cord injury medicine. 6. Economic and societal issues in spinal cord injury. Arch. Phys. Med. Rehabil. 88, Suppl 1, S84–S88.
4.
KruegerH., NoonanV.K., TrenamanL.M., JoshiP., and RiversC.S. (2013). The economic burden of traumatic spinal cord injury in Canada. Chronic Dis. Inj. Can. 33, 113–122.
5.
GeislerF.H., ColemanW.P., GriecoG., and PoonianD. (2001). The Sygen multicenter acute spinal cord injury study. Spine, 26, Suppl, S87–S98.
6.
FawcettJ.W., CurtA., SteevesJ.D., ColemanW.P., TuszynskiM.H., LammertseD., BartlettP.F., BlightA.R., DietzV., DitunnoJ., DobkinB.H., HavtonL.A., EllawayP.H., FehlingsM.G., PrivatA., GrossmanR., GuestJ.D., KleitmanN., NakamuraM., GaviriaM., and ShortD. (2007). Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord, 45, 190–205.
7.
KwonB.K., StammersA.M., BelangerL.M., BernardoA., ChanD., BishopC.M., SlobogeanG.P., ZhangH., UmedalyH., GiffinM., StreetJ., BoydM.C., PaquetteS.J., FisherC.G., and DvorakM.F. (2010). Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J. Neurotrauma, 27, 669–682.
8.
KwonB.K., StreijgerF., FallahN., NoonanV.K., BelangerL.M., RitchieL., PaquetteS.J., AilonT., BoydM.C., StreetJ., FisherC.G., and DvorakM.F. (2017). Cerebrospinal fluid biomarkers to stratify injury severity and predict outcome in human traumatic spinal cord injury. J. Neurotrauma, 34, 567–580.
9.
LaterzaO.F., LimL., Garrett-EngeleP.W., VlasakovaK., MuniappaN., TanakaW.K., JohnsonJ.M., SinaJ.F., FareT.L., SistareF.D., and GlaabW.E. (2009). Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin. Chem. 55, 1977–1983.
10.
MitchellP.S., ParkinR.K., KrohE.M., FritzB.R., WymanS.K., Pogosova-AgadjanyanE.L., PetersonA., NoteboomJ., O'BriantK.C., AllenA., LinD.W., UrbanN., DrescherC.W., KnudsenB.S., StirewaltD.L., GentlemanR., VessellaR.L., NelsonP.S., MartinD.B., and TewariM. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105, 10513–10518.
11.
WernerssonR., SchierupM.H., JorgensenF.G., GorodkinJ., PanitzF., StaerfeldtH.H., ChristensenO.F., MailundT., HornshojH., KleinA., WangJ., LiuB., HuS., DongW., LiW., WongG.K., YuJ., WangJ., BendixenC., FredholmM., BrunakS., YangH., and BolundL. (2005). Pigs in sequence space: a 0.66X coverage pig genome survey based on shotgun sequencing. BMC Genomics, 6, 70.
12.
TigchelaarS., StreijgerF., SinhaS., FlibotteS., ManouchehriN., SoK., ShorttK., OkonE., RizzutoM.A., MalenicaI., Courtright-LimA., EisenA., Keuren-JensenK.V., NislowC., and KwonB.K. (2017). Serum microRNAs reflect injury severity in a large animal model of thoracic spinal cord injury. Sci. Rep. 7, 1376.
13.
GongZ.M., TangZ.Y., and SunX.L. (2018). MiR-411 suppresses acute spinal cord injury via downregulation of Fas ligand in rats. Biochem. Biophys. Res. Commun. 501, 501–506.
14.
BrennanF.H. and PopovichP.G. (2018). Emerging targets for reprograming the immune response to promote repair and recovery of function after spinal cord injury. Curr. Opin. Neurol. 31, 334–344.
15.
HeY., LvB., HuanY., LiuB., LiY., JiaL., QuC., WangD., YuH., and YuanH. (2018). Zhenbao pill protects against acute spinal cord injury via miR-146a-5p regulating the expression of GPR17. Biosci. Rep. 38.
16.
BhomiaM., BalakathiresanN.S., WangK.K., PapaL., and MaheshwariR.K. (2016). A panel of serum miRNA biomarkers for the diagnosis of severe to mild traumatic brain injury in humans. Sci. Rep. 6, 28148.
17.
Nieto-DiazM., EstebanF.J., ReigadaD., Munoz-GaldeanoT., YuntaM., Caballero-LopezM., Navarro-RuizR., Del AguilaA., and MazaR.M. (2014). MicroRNA dysregulation in spinal cord injury: causes, consequences and therapeutics. Front. Cell. Neurosci. 8, 53.
18.
YuntaM., Nieto-DiazM., EstebanF.J., Caballero-LopezM., Navarro-RuizR., ReigadaD., Pita-ThomasD.W., del AguilaA., Munoz-GaldeanoT., and MazaR.M. (2012). MicroRNA dysregulation in the spinal cord following traumatic injury. PLoS One, 7, e34534.
19.
NingB., GaoL., LiuR.H., LiuY., ZhangN.S., and ChenZ.Y. (2014). MicroRNAs in spinal cord injury: potential roles and therapeutic implications. Int. J. Biol. Sci. 10, 997–1006.
20.
ShiZ., ZhouH., LuL., LiX., FuZ., LiuJ., KangY., WeiZ., PanB., LiuL., KongX., and FengS. (2017). The roles of microRNAs in spinal cord injury. Int. J. Neurosci. 127, 1104–1115.
21.
StricklandE.R., HookM.A., BalaramanS., HuieJ.R., GrauJ.W., and MirandaR.C. (2011). MicroRNA dysregulation following spinal cord contusion: implications for neural plasticity and repair. Neuroscience, 186, 146–160.
22.
BurgosK.L., JavaherianA., BomprezziR., GhaffariL., RhodesS., CourtrightA., TembeW., KimS., MetpallyR., and Van Keuren-JensenK. (2013). Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA, 19, 712–722.
23.
SunZ., EvansJ., BhagwateA., MiddhaS., BockolM., YanH., and KocherJ.P. (2014). CAP-miRSeq: a comprehensive analysis pipeline for microRNA sequencing data. BMC Genomics, 15, 423.
24.
FriedlanderM.R., MackowiakS.D., LiN., ChenW., and RajewskyN. (2012). MiRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res. 40, 37–52.
25.
LoveM.I., HuberW., and AndersS. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
26.
StreijgerF., SkinniderM.A., RogalskiJ.C., BalshawR., ShannonC.P., PrudovaA., BelangerL., RitchieL., TsangA., ChristieS., ParentS., Mac-ThiongJ.M., BaileyC., UrquhartJ., AilonT., PaquetteS., BoydM., StreetJ., FisherC.G., DvorakM.F., BorchersC.H., FosterL.J., and KwonB.K. (2017). A targeted proteomics analysis of cerebrospinal fluid after acute human spinal cord injury. J. Neurotrauma, 34, 2054–2068.
27.
Le CaoK.A., BoitardS., and BesseP. (2011). Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinformatics, 12, 253.
28.
LeshkowitzD., Horn-SabanS., ParmetY., and FeldmesserE. (2013). Differences in microRNA detection levels are technology and sequence dependent. RNA, 19, 527–538.
29.
Baran-GaleJ., KurtzC.L., ErdosM.R., SisonC., YoungA., FanninE.E., ChinesP.S., and SethupathyP. (2015). Addressing bias in small RNA library preparation for sequencing: a new protocol recovers microRNAs that evade capture by current methods. Front. Genet. 6, 352.
30.
LiuN.K., WangX.F., LuQ.B., and XuX.M. (2009). Altered microRNA expression following traumatic spinal cord injury. Exp. Neurol. 219, 424–429.
31.
LiP., TengZ.Q., and LiuC.M. (2016). Extrinsic and intrinsic regulation of axon regeneration by microRNAs after spinal cord injury. Neural Plast. 2016, 1279051.
32.
HachisukaS., KameiN., UjigoS., MiyakiS., YasunagaY., and OchiM. (2014). Circulating microRNAs as biomarkers for evaluating the severity of acute spinal cord injury. Spinal Cord, 52, 596–600.
33.
YuY.M., GibbsK.M., DavilaJ., CampbellN., SungS., TodorovaT.I., OtsukaS., SabaawyH.E., HartR.P., and SchachnerM. (2011). MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish. Eur. J. Neurosci. 33, 1587–1597.
34.
AndersenC.L., JensenJ.L., and OrntoftT.F. (2004). Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64, 5245–5250.
35.
LeeR.S., NoonanV.K., BatkeJ., GhagA., PaquetteS.J., BoydM.C., FisherC.G., StreetJ., DvorakM.F., and KwonB.K. (2012). Feasibility of patient recruitment into clinical trials of experimental treatments for acute spinal cord injury. J. Clin. Neurosci. 19, 1338–1343.
36.
FehlingsM.G., RabinD., SearsW., CadotteD.W., and AarabiB. (2010). Current practice in the timing of surgical intervention in spinal cord injury. Spine, 35, Suppl, S166–S173.
37.
MarincolaF.M. (2011). The trouble with translational medicine. J. Intern. Med. 270, 123–127.
38.
LauP., VerrierJ.D., NielsenJ.A., JohnsonK.R., NotterpekL., and HudsonL.D. (2008). Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J. Neurosci. 28, 11720–11730.
39.
KloostermanW.P. and PlasterkR.H. (2006). The diverse functions of microRNAs in animal development and disease. Dev. Cell, 11, 441–450.
40.
BhalalaO.G., PanL., SahniV., McGuireT.L., GrunerK., TourtellotteW.G., and KesslerJ.A. (2012). MicroRNA-21 regulates astrocytic response following spinal cord injury. J. Neurosci. 32, 17935–17947.
41.
BullerB., LiuX., WangX., ZhangR.L., ZhangL., Hozeska-SolgotA., ChoppM., and ZhangZ.G. (2010). MicroRNA-21 protects neurons from ischemic death. FEBS J. 277, 4299–4307.
42.
BoonH., SjogrenR.J., MassartJ., EganB., KostovskiE., IversenP.O., HjeltnesN., ChibalinA.V., WidegrenU., and ZierathJ.R. (2015). MicroRNA-208b progressively declines after spinal cord injury in humans and is inversely related to myostatin expression. Physiol. Rep. 3.
43.
BakM., SilahtarogluA., MollerM., ChristensenM., RathM.F., SkryabinB., TommerupN., and KauppinenS. (2008). MicroRNA expression in the adult mouse central nervous system. RNA, 14, 432–444.
44.
PatzS., TrattnigC., GrunbacherG., EbnerB., GullyC., NovakA., RinnerB., LeitingerG., AbsengerM., TomescuO.A., ThallingerG.G., FaschingU., WissaS., Archelos-GarciaJ., and SchaferU. (2013). More than cell dust: microparticles isolated from cerebrospinal fluid of brain injured patients are messengers carrying mRNAs, miRNAs, and proteins. J. Neurotrauma, 30, 1232–1242.
45.
YangT., SongJ., BuX., WangC., WuJ., CaiJ., WanS., FanC., ZhangC., and WangJ. (2016). Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury. J. Neurochem. 137, 122–129.
46.
JohnsonJ.J., LoeffertA.C., StokesJ., OlympiaR.P., BramleyH., and HicksS.D. (2018). Association of salivary microRNA changes with prolonged concussion symptoms. JAMA Pediatr. 172, 65–73.
47.
LeeJ.H., JonesC.F., OkonE.B., AndersonL., TigchelaarS., KoonerP., GodbeyT., ChuaB., GrayG., HildebrandtR., CriptonP., TetzlaffW., and KwonB.K. (2013). A novel porcine model of traumatic thoracic spinal cord injury. J. Neurotrauma, 30, 142–159.
48.
KimK.T., StreijgerF., ManouchehriN., SoK., ShorttK., OkonE.B., TigchelaarS., CriptonP., and KwonB.K. (2018). Review of the UBC porcine model of traumatic spinal cord injury. J. Korean Neurosurg. Soc. 61, 539–547.
49.
LiM.M., JiangT., SunZ., ZhangQ., TanC.C., YuJ.T., and TanL. (2014). Genome-wide microRNA expression profiles in hippocampus of rats with chronic temporal lobe epilepsy. Sci. Rep. 4, 4734.
50.
YokoboriS., ZhangZ., MoghiebA., MondelloS., GajavelliS., DietrichW.D., BramlettH., HayesR.L., WangM., WangK.K., and BullockM.R. (2015). Acute diagnostic biomarkers for spinal cord injury: review of the literature and preliminary research report. World Neurosurg. 83, 867–878.
51.
KuhleJ., GaiottinoJ., LeppertD., PetzoldA., BestwickJ.P., MalaspinaA., LuC.H., DobsonR., DisantoG., NorgrenN., NissimA., KapposL., HurlbertJ., YongV.W., GiovannoniG., and CashaS. (2015). Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J. Neurol. Neurosurg. Psychiatry, 86, 273–279.
52.
PouwM.H., KwonB.K., VerbeekM.M., VosP.E., van KampenA., FisherC.G., StreetJ., PaquetteS.J., DvorakM.F., BoydM.C., HosmanA.J., and van de MeentH. (2014). Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects. Spinal Cord, 52, 428–433.
53.
ZetterbergH., SmithD.H., and BlennowK. (2013). Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat. Rev. Neurol. 9, 201–210.
54.
WhiteleyW., WardlawJ., DennisM., LoweG., RumleyA., SattarN., WelshP., GreenA., AndrewsM., and SandercockP. (2012). The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke, 43, 86–91.
55.
JicklingG.C. and SharpF.R. (2011). Blood biomarkers of ischemic stroke. Neurotherapeutics, 8, 349–360.
56.
WuY., StreijgerF., WangY., LinG., ChristieS., Mac-ThiongJ.M., ParentS., BaileyC.S., PaquetteS., BoydM.C., AilonT., StreetJ., FisherC.G., DvorakM.F., KwonB.K., and LiL. (2016). Parallel metabolomic profiling of cerebrospinal fluid and serum for identifying biomarkers of injury severity after acute human spinal cord injury. Sci. Rep. 6, 38718.
57.
RedellJ.B., MooreA.N., WardN.H., 3rd, HergenroederG.W., and DashP.K. (2010). Human traumatic brain injury alters plasma microRNA levels. J. Neurotrauma, 27, 2147–2156.
58.
PouwM.H., HosmanA.J., van MiddendorpJ.J., VerbeekM.M., VosP.E., and van de MeentH. (2009). Biomarkers in spinal cord injury. Spinal Cord, 47, 519–525.
59.
KwonB.K., CashaS., HurlbertR.J., and YongV.W. (2011). Inflammatory and structural biomarkers in acute traumatic spinal cord injury. Clin. Chem. Lab. Med. 49, 425–433.
60.
AhmedF., GyorgyA., KamnakshA., LingG., TongL., ParksS., and AgostonD. (2012). Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury. Electrophoresis, 33, 3705–3711.
61.
AhadiR., KhodagholiF., DaneshiA., VafaeiA., MafiA.A., and JorjaniM. (2015). Diagnostic value of serum levels of GFAP, pNF-H, and NSE compared with clinical findings in severity assessment of human traumatic spinal cord injury. Spine, 40, E823–E830.
62.
LubienieckaJ.M., StreijgerF., LeeJ.H., StoynovN., LiuJ., MottusR., PfeiferT., KwonB.K., CoorssenJ.R., FosterL.J., GrigliattiT.A., and TetzlaffW. (2011). Biomarkers for severity of spinal cord injury in the cerebrospinal fluid of rats. PLoS One, 6, e19247.
63.
ElizeiS.S. and KwonB.K. (2017). The translational importance of establishing biomarkers of human spinal cord injury. Neural Regen. Res. 12, 385–388.
64.
DalkilicT., FallahN., NoonanV.K., Salimi ElizeiS., DongK., BelangerL., RitchieL., TsangA., Bourassa-MoreauE., HeranM.K., PaquetteS.J., AilonT., DeaN., StreetJ., FisherC.G., DvorakM.F., and KwonB.K. (2018). Predicting injury severity and neurological recovery after acute cervical spinal cord injury: a comparison of cerebrospinal fluid and magnetic resonance imaging biomarkers. J. Neurotrauma, 35, 435–445.
65.
BadhiwalaJ.H., WilsonJ.R., KwonB.K., CashaS., and FehlingsM.G. (2018). A review of clinical trials in spinal cord injury including biomarkers. J. Neurotrauma, 35, 1906–1917.
66.
SquairJ.W., TigchelaarS., MoonK.M., LiuJ., TetzlaffW., KwonB.K., KrassioukovA.V., WestC.R., FosterL.J., and SkinniderM.A. (2018). Integrated systems analysis reveals conserved gene networks underlying response to spinal cord injury. Elife. 7.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
